Cargando…
COVID-19 Vaccine Hesitancy among Patients with Inflammatory Bowel Disease Receiving Biologic Therapies in Kuwait: A Cross-Sectional Study
Background: COVID-19 vaccinations have been shown to be effective in reducing risk of severe infection, hospitalization, and death. They have also been shown to be safe and effective in patients with inflammatory bowel disease (IBD) who are receiving biologic therapies. In this study, we aimed to ev...
Autores principales: | Shehab, Mohammad, Zurba, Yasmin, Al Abdulsalam, Ali, Alfadhli, Ahmad, Elouali, Sara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777753/ https://www.ncbi.nlm.nih.gov/pubmed/35062716 http://dx.doi.org/10.3390/vaccines10010055 |
Ejemplares similares
-
Exploring the Pipeline of Novel Therapies for Inflammatory Bowel Disease; State of the Art Review
por: Zurba, Yasmin, et al.
Publicado: (2023) -
COVID-19 Vaccine Booster Dose Willingness among Patients with Inflammatory Bowel Disease on Infliximab and Vedolizumab: A Cross-Sectional Study
por: Shehab, Mohammad, et al.
Publicado: (2022) -
Kuwait Recommendations on Vaccine Use in People with Inflammatory Rheumatic Diseases
por: AlEnizi, Ahmad, et al.
Publicado: (2018) -
Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study)
por: Alrashed, Fatema, et al.
Publicado: (2023) -
Inflammatory Bowel Disease in Children, an Evolving Problem in Kuwait
por: Al-Qabandi, Wafa’a A., et al.
Publicado: (2011)